Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (ACET) is a clinical-stage biotechnology company pioneering allogeneic gamma delta T cell therapies for cancer treatment. This page serves as the definitive source for verified corporate developments, research milestones, and strategic updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapy pipeline advancements, financial disclosures, and scientific collaborations, with particular focus on the company's CAR/TCR engineering platform and TCR-like antibody research.
Key content categories include updates on lead candidate ADI-001 for B-cell malignancies, preclinical developments for solid tumor targets like CD70, and strategic initiatives such as the Regeneron Pharmaceuticals collaboration. All materials are vetted for accuracy and relevance to investment analysis.
Bookmark this page for streamlined access to essential updates about Adicet Bio's innovative approach to universal cell therapies. Check regularly for new developments in their mission to advance off-the-shelf immunotherapies for oncology applications.
Adicet Bio (Nasdaq: ACET) has announced FDA clearance for its IND application for ADI-270, a gamma delta CAR T cell therapy targeting CD70+ cancers, specifically for relapsed/refractory renal cell carcinoma (RCC).
ADI-270 is the first gamma delta 1 CAR T cell therapy to enter clinical development for solid tumors. A Phase 1 clinical trial to evaluate its safety and anti-tumor activity is set to begin in the second half of 2024, with preliminary data expected in the first half of 2025.
The trial will be a multicenter, open-label study focusing on adults with relapsed/refractory clear cell RCC. Participants will receive a single dose of ADI-270 following lymphodepletion, with potential second doses based on meeting specific criteria. The trial aims to assess safety, tolerability, pharmacokinetics, and anti-tumor activity, including overall response rate and disease control rate.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech firm, has received FDA Fast Track Designation for its ADI-001 therapy aimed at treating relapsed/refractory class III or IV lupus nephritis. The designation highlights the urgent need for new treatments for this chronic disease. Adicet Bio plans to initiate a Phase 1 clinical study for lupus nephritis this month. Previous clinical data for ADI-001 in non-Hodgkin’s lymphoma showed promising CD19+ B-cell depletion, comparable to results seen in autologous alpha-beta CAR T treatments in various autoimmune diseases. The company is optimistic about expanding its autoimmune program and will soon provide investors with an update.
Adicet Bio, a clinical-stage biotechnology company, announced inducement grants under Nasdaq Listing Rule 5635(c)(4) on May 31, 2024. The company hired two new employees in May 2024 and granted them non-qualified stock options to purchase a total of 44,800 shares of common stock at $1.45 per share. The stock options will vest over four years, with one-fourth vesting after one year and the remaining three-fourths vesting in equal monthly installments over the next three years. These awards were granted outside the company’s stockholder-approved equity incentive plans under the 2022 Inducement Plan, authorized by the compensation committee comprised of independent directors.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech firm, announced that its CEO, Chen Schor, will participate in a fireside chat at the Jefferies Healthcare Conference in New York. The event is scheduled for June 5, 2024, at 1:00 p.m. ET. Adicet specializes in allogeneic gamma delta T cell therapies targeting autoimmune diseases and cancer. The live audio webcast and a 30-day archived replay will be accessible on Adicet Bio's website.
Adicet Bio (Nasdaq: ACET) has reported its Q1 2024 financial results and key business updates. The company is set to initiate a Phase 1 clinical trial for ADI-001 in lupus nephritis in Q2 2024, following FDA clearance. Preliminary data is expected by late 2024 or early 2025. Adicet also presented promising preclinical data on ADI-270 at the ASGCT annual meeting, with plans to file an IND for ADI-270 in renal cell carcinoma in Q2 2024. Financially, the company has a robust balance sheet with $247.6 million in cash and equivalents, projecting fund sufficiency until the second half of 2026. R&D expenses decreased to $23.9 million from $26.8 million YoY, while G&A expenses increased slightly to $7.0 million from $6.6 million YoY. Net loss for Q1 2024 was $28.0 million, or $0.35 per share, an improvement from $30.9 million, or $0.72 per share, in Q1 2023.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech firm specializing in gamma delta T cell therapies for autoimmune diseases and cancer, will present preclinical data on ADI-270 at the 2024 European Hematology Association (EHA) Hybrid Congress. The event, held in Madrid, Spain from June 13-16, 2024, will feature Yvan Chanthery, Ph.D., presenting on June 14 at 18:00 CEST. ADI-270 is an armored allogeneic anti-CD70 CAR γδ T cell therapy aimed at multiple solid and hematological cancers.
Adicet Bio, Inc. (Nasdaq: ACET) will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference in New York. Chen Schor, President and CEO, will present on May 14, 2024, at 1:30 p.m. ET. The presentation can be accessed on the Investors section of Adicet Bio's website.
Adicet Bio, Inc. (Nasdaq: ACET) granted an inducement award on April 30, 2024, to a new employee. The award consists of non-qualified stock options to purchase 7,800 shares at $1.49 per share. Vesting occurs over four years, with one-fourth vesting after one year and the rest in monthly installments. The award was granted outside Adicet's equity plans under the Inducement Plan.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
